26/10/2014 04:42:24 Free Membership Login

Immupharma News (LSE:IMM)

DateTimeSource
Headline
10/20/20142:59AMALNCImmuPharma Gets EUR400,000 Grant In France For Urelix Technology
LONDON (Alliance News) - ImmuPharma PLC Monday said the French region of Acquitane in the Bordeaux region of the country has awarded its Ureka subsidiary with a EUR400,000 grant. The funding has been awarded to the company's subsidiary to develop its Urelix technology, which mimics natural peptides having a helical conformation... More...>>
09/30/20145:27AMALNCImmuPharma Poised For Phase III Trials Of Lupuzor As Loss As Expected
LONDON (Alliance News) - ImmuPharma PLC Tuesday said its key compound, lupus treatment Lupuzor, will soon enter phase III trials as it posted an in-line pretax loss for the half year to end-June. The company posted a pretax loss of GBP1.8 million, broadly flat on the previous year as it maintained its level of operating... More...>>
05/06/20147:47AMRNSNONImmupharma PLC Dr. Sylviane Muller - Presentation Abstract
TIDMIMM RNS Number : 3468G Immupharma PLC 06 May 2014 FOR IMMEDIATE RELEASE RNS REACH* 6 MAY 2014 Dr. Sylviane Muller - Presentation Abstract from 2014 European Lupus Conference ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, provides a summary of the presentation... More...>>
04/23/20142:00AMRNSNONImmupharma PLC Dr. S Muller, founder of Lupuzor presentation.
TIDMIMM RNS Number : 2687F Immupharma PLC 23 April 2014 FOR IMMEDIATE RELEASE RNS REACH 23 APRIL 2014 Dr. Slyviane Muller, founder of Lupuzor, presents at Osaka University, Japan ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announced that... More...>>
04/11/20142:00AMRNSNONImmupharma PLC ImmuPharma Sponsors the 2014 European Lupus Confer
TIDMIMM RNS Number : 5939E Immupharma PLC 11 April 2014 FOR IMMEDIATE RELEASE RNS REACH 11 APRIL 2014 ImmuPharma Sponsors the 2014 European Lupus Conference Presentation Date: 24 April 2014 ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to confirm... More...>>
07/08/20133:00AMRNSNONImmupharma PLC IMMUPHARMA APPOINTS WORLDWIDE KEY OPINION LEADERS
TIDMIMM RNS Number : 7772I Immupharma PLC 08 July 2013 8 July 2013 ImmuPharma PLC IMMUPHARMA APPOINTS WORLDWIDE KEY OPINION LEADERS TO SCIENTIFIC ADVISORY BOARD FOR LUPUZOR PHASE III ImmuPharma plc (LSE:IMM) ("ImmuPharma" or the "Company" or the "Group"), the specialist drug discovery and development company, is delighted... More...>>
02/28/20132:02AMRNSNONImmupharma PLC ImmuPharma Commences Trading on Stuttgart Exchange
TIDMIMM RNS Number : 8448Y Immupharma PLC 28 February 2013 FOR IMMEDIATE RELEASE 28 FEBRUARY 2013 RNS REACH ImmuPharma PLC Commences Trading on the Stuttgart Stock Exchange ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announces that it... More...>>
01/28/20134:33AMRNSNONImmupharma PLC CNRS Confirms Lupuzor's (TM) Effectiveness
TIDMIMM RNS Number : 4761W Immupharma PLC 28 January 2013 FOR IMMEDIATE RELEASE 28 JANUARY 2013 RNS REACH CNRS Confirms Lupuzor's (TM) Effectiveness ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce that its key scientific collaboration... More...>>
11/05/20122:00AMRNSNONImmupharma PLC Lupuzor Presentation
TIDMIMM RNS Number : 2719Q Immupharma PLC 05 November 2012 FOR IMMEDIATE RELEASE 5 NOVEMER 2012 RNS REACH ImmuPharma to Present Lupuzor(TM) Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C. Presentation Date: 14 November 2012 ImmuPharma PLC (LSE: IMM), ("ImmuPharma" or the "Company"), the... More...>>
09/07/20126:12AMRNSNONImmupharma PLC Rodman and Renshaw Conference
TIDMIMM RNS Number : 7713L Immupharma PLC 07 September 2012 FOR IMMEDIATE RELEASE 7 SEPTEMBER 2012 RNS REACH ImmuPharma to Present at Rodman and Renshaw Annual Global Investment Conference, New York Tuesday 11 September 2012 ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development... More...>>
07/11/20122:00AMRNSNONImmupharma PLC Voted Best Medical Research & Development Company
TIDMIMM RNS Number : 3670H Immupharma PLC 11 July 2012 FOR IMMEDIATE RELEASE 11 July 2012 RNS REACH ImmuPharma PLC Voted Best Medical Research and Development Company, Europe 2012 ImmuPharma PLC (LSE: IMM) ("ImmuPharma" or the "Company"), the specialist discovery and development pharmaceutical company, has been voted "Best... More...>>
07/09/20122:00AMRNSNONImmupharma PLC New Corporate Website
TIDMIMM RNS Number : 1708H Immupharma PLC 09 July 2012 FOR IMMEDIATE RELEASE 9 July 2012 RNS REACH IMMUPHARMA LAUNCHES NEW CORPORATE WEBSITE PROVDING GREATER CLARITY ON LUPUZOR, CANCER AND ITS DEVELOPMENT PIPELINE ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug development company has today... More...>>
02/29/20122:02AMRNSNONAppoints Head of Investor Relations
TIDMIMM RNS Number : 3054Y Immupharma PLC 29 February 2012 FOR IMMEDIATE RELEASE 29 FEBRUARY 2012 ImmuPharma plc Appoints Head of Investor Relations ImmuPharma plc (AIM: IMM), the specialist drug development company, is pleased to announce that it has appointed Lisa Baderoon as Head of Investor Relations. Lisa Baderoon... More...>>
11/03/20114:20AMDJNImmuPharma In Lupuzor Licensing Talks As FDA Says Trials Can Begin
U.K. drug discovery company ImmuPharma PLC (IMM.LN) Thursday said U.S. regulators have given it the green light to begin a Phase III trial for its flagship drug Lupuzor, and said it is in talks with pharmaceutical companies regarding a potential licensing deal for the Lupus treatment. ImmuPharma said the U.S. Food and... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us lse imm141026 04:42